[go: up one dir, main page]

WO2013069016A3 - Long lasting drug formulations - Google Patents

Long lasting drug formulations Download PDF

Info

Publication number
WO2013069016A3
WO2013069016A3 PCT/IL2012/050448 IL2012050448W WO2013069016A3 WO 2013069016 A3 WO2013069016 A3 WO 2013069016A3 IL 2012050448 W IL2012050448 W IL 2012050448W WO 2013069016 A3 WO2013069016 A3 WO 2013069016A3
Authority
WO
WIPO (PCT)
Prior art keywords
long lasting
drug formulations
lasting drug
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2012/050448
Other languages
French (fr)
Other versions
WO2013069016A2 (en
Inventor
Andrew L. Pearlman
Baruch S. Stern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medgenics Medical Israel Ltd
Original Assignee
Medgenics Medical Israel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/346,761 external-priority patent/US8454948B2/en
Application filed by Medgenics Medical Israel Ltd filed Critical Medgenics Medical Israel Ltd
Publication of WO2013069016A2 publication Critical patent/WO2013069016A2/en
Publication of WO2013069016A3 publication Critical patent/WO2013069016A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.
PCT/IL2012/050448 2011-11-09 2012-11-08 Long lasting drug formulations Ceased WO2013069016A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161557451P 2011-11-09 2011-11-09
US61/557,451 2011-11-09
US13/346,761 US8454948B2 (en) 2006-09-14 2012-01-10 Long lasting drug formulations
US13/346,761 2012-01-10
US201261672962P 2012-07-18 2012-07-18
US61/672,962 2012-07-18

Publications (2)

Publication Number Publication Date
WO2013069016A2 WO2013069016A2 (en) 2013-05-16
WO2013069016A3 true WO2013069016A3 (en) 2013-07-18

Family

ID=48290712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2012/050448 Ceased WO2013069016A2 (en) 2011-11-09 2012-11-08 Long lasting drug formulations

Country Status (1)

Country Link
WO (1) WO2013069016A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059701A1 (en) * 2013-10-24 2015-04-30 Medgenics Medical Israel Ltd. Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
US20190030128A1 (en) * 2016-01-11 2019-01-31 Medgenics Medical Israel Ltd. Compositions and Methods for Treatment of Central Nervous System Diseases
CN110531090A (en) * 2019-08-30 2019-12-03 西北大学 The purposes of hemoglobin and haemoglobin dervative in terms of preparing for the injection pharmaceutical preparation of anti-anemia action
WO2025141778A1 (en) * 2023-12-27 2025-07-03 中外製薬株式会社 Novel promoter

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090777A1 (en) * 2006-09-14 2008-04-17 Pearlman Andrew L Long lasting drug formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090777A1 (en) * 2006-09-14 2008-04-17 Pearlman Andrew L Long lasting drug formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIPPIN, Y ET AL.: "Human Erythropoietin Gene Thereapy For Patients With Chronic Renal Failure.", BLOOD., vol. 106, no. 7, 1 October 2005 (2005-10-01), pages 2290 - 2296 *
MITRANI, E ET AL.: "Biopump: Autologous Skin-Derived Micro-Organ Genetically Engineered To Provide Sustained Continuous Secretion Of Therapeutic Proteins.", DERMATOLOGIC THERAPY., vol. 24, 2011, pages 489 - 497 *

Also Published As

Publication number Publication date
WO2013069016A2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
WO2008033375A3 (en) Long lasting drug formulations
WO2017218974A3 (en) Treatment of amd using aav2 variant with aflibercept
WO2016170348A8 (en) Sarna compositions and methods of use
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2017070626A3 (en) Respiratory virus vaccines
WO2012168431A3 (en) Polypeptides
WO2018089851A3 (en) Influenza vaccine
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2011094358A9 (en) Influenza nucleic acid molecules and vaccines made therefrom
WO2012027728A3 (en) Compositions and methods for targeted thermomodulation
WO2012021715A3 (en) Stable formulations of linaclotide
DK2579900T3 (en) VECTORS AND SEQUENCES FOR THE TREATMENT OF DISEASES
WO2015006747A3 (en) Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2017218981A3 (en) Compositions and methods for reducing ocular neovascularization
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
DK2707393T3 (en) FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
BR112013031505A2 (en) "polypeptide, use of a polypeptide, nucleic acid molecule, vector, host, vaccine formulations, and uses of a vaccine formulation
WO2013170170A3 (en) Compositions and methods for gene therapy
EA201370018A1 (en) COMPOSITIONS OF RIFAXIMINE AND THEIR APPLICATION
WO2011159758A3 (en) Long lasting drug formulations
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12848222

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12848222

Country of ref document: EP

Kind code of ref document: A2